source
- Novartis drops mid-stage radioligand therapy 177Lu-NeoB after weak early dataNovartis has discontinued its mid-stage radioligand therapy 177Lu-NeoB, which was being tested for breast cancer and other solid tumors. The company said early clinical data did not show enough ef…
- Nabla executive Alex LeBrun discusses ‘world model’ AI as an alternative to large language modelsBrittany Trang of STAT’s AI Prognosis newsletter interviewed Alex LeBrun, the executive chairman of AI scribe company Nabla, to explore a concept called a “world model.” LeBrun described a world m…